Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology, has announced its participation in the upcoming Needham Virtual Healthcare Conference.

The company's President and CEO, Zachary Hornby, will deliver a presentation on Thursday, April 10, 2025, at 1:30 p.m. ET. Investors and interested parties can access both the live and archived webcasts of the presentation through the 'Events & Presentations' section of Boundless Bio's website or directly via the provided webcast link.

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Needham’s Virtual Healthcare Conference.

A company presentation is scheduled for Thursday, April 10, 2025, at 1:30 p.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: https://wsw.com/webcast/needham146/bold/2230221.

About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Leveraging its Spyglass platform, Boundless Bio has additional ecDTx programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA. For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) presenting at the Needham Virtual Healthcare Conference?

Boundless Bio will present on Thursday, April 10, 2025, at 1:30 p.m. ET.

How can investors access Boundless Bio's (BOLD) Needham Conference presentation?

Investors can access the live and archived webcast through Boundless Bio's website under 'Events & Presentations' or via the direct webcast link.

What is Boundless Bio's (BOLD) main research focus?

Boundless Bio focuses on extrachromosomal DNA (ecDNA) biology to develop therapies for oncogene amplified cancers.

Who will represent Boundless Bio (BOLD) at the Needham Healthcare Conference?

Zachary Hornby, President and Chief Executive Officer, will represent Boundless Bio at the conference.